Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Clinical trial NCT07018427 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07018427
Sponsor: Peking University Cancer Hospital & Institute
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Breast Neoplasms Triple Negative Breast Cancer HR+, HER2-, Advanced Breast Cancer Breast Cancer

Start date: 2023-05-01
Primary completion: 2025-05-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.